Pfizer and AbbVie shares declined more than 4%, Merck dropped almost 4%, and Eli Lilly pulled back over 3% in early trading. Daily Merck & Company, Inc. Dow pharmaceutical components are leading ...

Healthcare & Pharmaceuticalscategory· March 28, 2025 Merck plans to launch US subcutaneous version of Keytruda on October 1 Merck & Co said on Thursday that it plans to launch a subcutaneously ...

More than 200 members of the United Steelworkers Union Local 10-00086 at Merck & Co. rallied outside Building 53 near Gate 1 at the Upper Gwynedd pharmaceutical giant Wednesday afternoon in support of ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab).

Mer­ck KGaA is spend­ing $85 mil­lion to tap glob­al com­mer­cial­iza­tion rights to pim­i­co­tinib, a can­di­date for non-ma­lig­nant tu­mors that it li­censed from Chi­na’s ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia. The ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay. In a push to keep the Keytruda gravy train on the ...

Merck has shared data from the pivotal 3475A-D77 Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together with berahyaluronidase alfa (subcutaneous pembrolizumab). The study ...

German life sciences and pharma company Merck KGaA (MRK: DE) today revealed it has exercised its option with China’s Abbisko Therapeutics (HKEX: 02256) for commercialization of pimicotinib in the US ...

which is known as MSD outside the US and Canada. Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the ...

Mer­ck shared Phase 3 da­ta show­ing that an in­jectable ver­sion of its block­buster can­cer drug Keytru­da is com­pa­ra­ble to the ap­proved … ...